Javier Pinilla-Ibarz, MD, PhD, is physician scientist Senior Member, Head of Lymphoma Section and Director of Immunotherapy in the Malignant Hematology Department at H. Lee Moffitt Cancer Center in Tampa, Florida. Dr. Pinilla-Ibarz is also a Professor in the Department of Oncologic Sciences, College of Medicine, University of South Florida.

Dr. Pinilla-Ibarz has been leading the chronic leukemia program at Moffitt since 2006, and its principal interests in the clinic are patients with myeloid and lymphoid chronic leukemia. Dr. Pinilla-Ibarz has participated in multiple clinical trials involving several kinase inhibitors, many of them now FDA approved.
He has been involved in developing new immunotherapeutic approaches in malignant hematology with special emphasis of restoring the impaired immune response of patients with chronic leukemias. He has participated in several clinical trials of peptide and cellular vaccines in different hematological disorders. He has been involved in the development of a Wilms tumor 1 vaccine for leukemias and other solid tumor now in phase III trial across the world. His laboratory is interested in epigenetic immunoregulation in lymphoid malignancies such as B and T cell lymphomas through the use of epigenetic modifiers such as histone deacetylase inhibitors and hypomethylating agents. Other research focuses are on the interaction of kinase inhibitors with the immune system and how to use these drugs to improve current immune therapeutics approaches.